83 related articles for article (PubMed ID: 16325149)
1. Role of GADD34 in modulation of cisplatin cytotoxicity.
Fishel ML; Rabik CA; Bleibel WK; Li X; Moschel RC; Dolan ME
Biochem Pharmacol; 2006 Jan; 71(3):239-47. PubMed ID: 16325149
[TBL] [Abstract][Full Text] [Related]
2. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
Fishel ML; Newell DR; Griffin RJ; Davison R; Wang LZ; Curtin NJ; Zuhowski EG; Kasza K; Egorin MJ; Moschel RC; Dolan ME
J Pharmacol Exp Ther; 2005 Jan; 312(1):206-13. PubMed ID: 15304523
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.
Fishel ML; Delaney SM; Friesen LD; Hansen RJ; Zuhowski EG; Moschel RC; Egorin MJ; Dolan ME
Mol Cancer Ther; 2003 Jul; 2(7):633-40. PubMed ID: 12883036
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.
Rabik CA; Fishel ML; Holleran JL; Kasza K; Kelley MR; Egorin MJ; Dolan ME
J Pharmacol Exp Ther; 2008 Nov; 327(2):442-52. PubMed ID: 18664592
[TBL] [Abstract][Full Text] [Related]
5. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.
Fishel ML; Gamcsik MP; Delaney SM; Zuhowski EG; Maher VM; Karrison T; Moschel RC; Egorin MJ; Dolan ME
Cancer Chemother Pharmacol; 2005 Apr; 55(4):333-342. PubMed ID: 15723259
[TBL] [Abstract][Full Text] [Related]
6. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.
Adusumilli PS; Chan MK; Chun YS; Hezel M; Chou TC; Rusch VW; Fong Y
Cancer Biol Ther; 2006 Jan; 5(1):48-53. PubMed ID: 16294031
[TBL] [Abstract][Full Text] [Related]
8. Microarray-analysis: a new approach to study the molecular mechanisms of thermo-chemotherapy.
Schulte JH; Schramm A; Pressel T; Klein-Hitpass L; Kremens B; Eils J; Havers W; Eggert A
Klin Padiatr; 2003; 215(6):298-302. PubMed ID: 14677092
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.
Arienti C; Zoli W; Pignatta S; Carloni S; Paganelli G; Ulivi P; Romeo A; Menghi E; Sarnelli A; Medri L; Polico R; Silvestrini R; Tesei A
J Cell Physiol; 2014 Oct; 229(10):1548-56. PubMed ID: 24591063
[TBL] [Abstract][Full Text] [Related]
11. The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2.
Harrison LR; Ottley CJ; Pearson DG; Roche C; Wedge SR; Dolan ME; Newell DR; Tilby MJ
Biochem Pharmacol; 2009 May; 77(10):1586-92. PubMed ID: 19426695
[TBL] [Abstract][Full Text] [Related]
12. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
Gaddameedhi S; Chatterjee S
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
[TBL] [Abstract][Full Text] [Related]
13. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
Thomadaki H; Scorilas A
Biol Chem; 2008 Nov; 389(11):1427-34. PubMed ID: 18783338
[TBL] [Abstract][Full Text] [Related]
14. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
Wang G; Dombkowski A; Chuang L; Xu XX
Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
[TBL] [Abstract][Full Text] [Related]
15. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
16. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
18. A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response.
Kruse JJ; Svensson JP; Huigsloot M; Giphart-Gassler M; Schoonen WG; Polman JE; Jean Horbach G; van de Water B; Vrieling H
Mutat Res; 2007 Apr; 617(1-2):58-70. PubMed ID: 17327130
[TBL] [Abstract][Full Text] [Related]
19. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
Marathi UK; Dolan ME; Erickson LC
Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
[TBL] [Abstract][Full Text] [Related]
20. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.
Almeida GM; Duarte TL; Farmer PB; Steward WP; Jones GD
Int J Cancer; 2008 Apr; 122(8):1810-9. PubMed ID: 18074354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
